LineaBio

Executive Summary

LineaBio is a private synthetic biology company headquartered in Berkeley, California, founded in 2019. The company specializes in engineering microbial strains and synthetic biology platforms for the production of therapeutics and industrial biologics. By leveraging advanced genetic engineering and metabolic pathway optimization, LineaBio aims to enable cost-effective, scalable manufacturing of complex biologic drugs and industrial enzymes. The company operates at the platform stage, indicating that its technology is designed to be broadly applicable across multiple product areas, reducing risk relative to single-asset biotechs. While the company has not disclosed total funding or valuation, its positioning in the rapidly growing synthetic biology sector, combined with the demand for sustainable biologics production, suggests significant potential. LineaBio faces competition from other synthetic biology firms such as Ginkgo Bioworks and Amyris, but its focus on therapeutics may differentiate it. Key risks include early-stage commercialization challenges, regulatory hurdles, and the need for substantial capital to advance platforms. Overall, the company's platform approach and experienced team (implied by Berkeley location) provide a foundation for future growth, though near-term revenue is unlikely. The following catalysts could drive near-term value.

Upcoming Catalysts (preview)

• 2026Series A or Series B Funding Round70% success
• 2026-2027Strategic Partnership with Pharma or Industrial Biotech Company50% success
• 2026Publication or Presentation of Platform Validation Data60% success